253 related articles for article (PubMed ID: 36124682)
1. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract][Full Text] [Related]
2. Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance.
Plaza-Menacho I; Morandi A; Robertson D; Pancholi S; Drury S; Dowsett M; Martin LA; Isacke CM
Oncogene; 2010 Aug; 29(33):4648-57. PubMed ID: 20531297
[TBL] [Abstract][Full Text] [Related]
3. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
4. Bromodomain protein BRD4 is required for estrogen receptor-dependent enhancer activation and gene transcription.
Nagarajan S; Hossan T; Alawi M; Najafova Z; Indenbirken D; Bedi U; Taipaleenmäki H; Ben-Batalla I; Scheller M; Loges S; Knapp S; Hesse E; Chiang CM; Grundhoff A; Johnsen SA
Cell Rep; 2014 Jul; 8(2):460-9. PubMed ID: 25017071
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
6. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
7. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
8. H4K12ac is regulated by estrogen receptor-alpha and is associated with BRD4 function and inducible transcription.
Nagarajan S; Benito E; Fischer A; Johnsen SA
Oncotarget; 2015 Mar; 6(9):7305-17. PubMed ID: 25788266
[TBL] [Abstract][Full Text] [Related]
9. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
[TBL] [Abstract][Full Text] [Related]
10. CircPVT1 promotes ER-positive breast tumorigenesis and drug resistance by targeting ESR1 and MAVS.
Yi J; Wang L; Hu GS; Zhang YY; Du J; Ding JC; Ji X; Shen HF; Huang HH; Ye F; Liu W
EMBO J; 2023 May; 42(10):e112408. PubMed ID: 37009655
[TBL] [Abstract][Full Text] [Related]
11. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen Resistance in Breast Cancer Is Regulated by the EZH2-ERα-GREB1 Transcriptional Axis.
Wu Y; Zhang Z; Cenciarini ME; Proietti CJ; Amasino M; Hong T; Yang M; Liao Y; Chiang HC; Kaklamani VG; Jeselsohn R; Vadlamudi RK; Huang TH; Li R; De Angelis C; Fu X; Elizalde PV; Schiff R; Brown M; Xu K
Cancer Res; 2018 Feb; 78(3):671-684. PubMed ID: 29212856
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.
Spanheimer PM; Park JM; Askeland RW; Kulak MV; Woodfield GW; De Andrade JP; Cyr AR; Sugg SL; Thomas A; Weigel RJ
Clin Cancer Res; 2014 Apr; 20(8):2115-25. PubMed ID: 24526731
[TBL] [Abstract][Full Text] [Related]
14. Distinct Roles for BET Family Members in Estrogen Receptor α Enhancer Function and Gene Regulation in Breast Cancer Cells.
Murakami S; Li R; Nagari A; Chae M; Camacho CV; Kraus WL
Mol Cancer Res; 2019 Dec; 17(12):2356-2368. PubMed ID: 31551256
[TBL] [Abstract][Full Text] [Related]
15. LEM4 confers tamoxifen resistance to breast cancer cells by activating cyclin D-CDK4/6-Rb and ERα pathway.
Gao A; Sun T; Ma G; Cao J; Hu Q; Chen L; Wang Y; Wang Q; Sun J; Wu R; Wu Q; Zhou J; Liu L; Hu J; Dong JT; Zhu Z
Nat Commun; 2018 Oct; 9(1):4180. PubMed ID: 30301939
[TBL] [Abstract][Full Text] [Related]
16. The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen-dependent gene required for the growth of estrogen receptor positive breast cancer cells.
Wang C; Mayer JA; Mazumdar A; Brown PH
Breast Cancer Res Treat; 2012 Jun; 133(2):487-500. PubMed ID: 21947652
[TBL] [Abstract][Full Text] [Related]
17. Histone methyltransferases regulate the transcriptional expression of ERα and the proliferation of tamoxifen-resistant breast cancer cells.
Kim SS; Lee MH; Lee MO
Breast Cancer Res Treat; 2020 Feb; 180(1):45-54. PubMed ID: 31897900
[TBL] [Abstract][Full Text] [Related]
18. Delineation of a FOXA1/ERα/AGR2 regulatory loop that is dysregulated in endocrine therapy-resistant breast cancer.
Wright TM; Wardell SE; Jasper JS; Stice JP; Safi R; Nelson ER; McDonnell DP
Mol Cancer Res; 2014 Dec; 12(12):1829-39. PubMed ID: 25100862
[TBL] [Abstract][Full Text] [Related]
19. Ctr9, a key subunit of PAFc, affects global estrogen signaling and drives ERα-positive breast tumorigenesis.
Zeng H; Xu W
Genes Dev; 2015 Oct; 29(20):2153-67. PubMed ID: 26494790
[TBL] [Abstract][Full Text] [Related]
20. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]